VERA
Vera Therapeutics, Inc. (VERA) Business Model Analysis (2026)
Overall Score
Revenue Model
No meaningful revenue is reported in the latest TTM metrics, with revenue per share at 0 and price-to-sales at 0, indicating an unproven monetization base.
The business is still generating negative operating and free cash flow, so the model is not yet demonstrating durable commercial traction.
Profitability
TTM margins are effectively zero across gross, operating, EBITDA, pretax, and net profit, showing no current profitability.
Returns remain deeply negative, including ROA of -75.4%, ROE of -84.1%, and ROIC of -85.8%, underscoring severe earnings weakness.
Balance Sheet
Liquidity remains very strong, with a current ratio of 10.9x and cash ratio of 1.0x, providing substantial near-term flexibility.
Leverage is modest, with debt-to-equity at 0.18x and net debt to EBITDA near zero, but the negative EBITDA base makes leverage metrics less meaningful.
Cash Flow
Operating cash flow and free cash flow remain negative, with FCF per share at -4.72 and FCF yield at -16.1%, indicating ongoing cash burn.
Cash conversion remains poor, with negative operating cash flow coverage and very weak interest coverage, reflecting limited internal funding capacity.
Valuation
Traditional earnings and cash-flow multiples are not meaningful because EBITDA, operating cash flow, and free cash flow are negative.
The stock still screens as asset-backed rather than earnings-backed, with price-to-book at 5.17x and book value per share at 5.68.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Vera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

